Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)
NCT ID: NCT01685424
Last Updated: 2022-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
79189 participants
OBSERVATIONAL
2006-06-30
2015-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)
NCT01572675
Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)
NCT00757627
Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)
NCT00242489
A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)
NCT00092768
Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)
NCT00092703
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Etoricoxib Prescription (Period 1)
First Etoricoxib Prescription, Apr. 1, 2002 to Feb. 17, 2005
Etoricoxib
As per routine clinical practice in the United Kingdom
Etoricoxib Prescription (Period 2)
First Etoricoxib Prescription, Feb. 18, 2005 to Dec. 31, 2015
Etoricoxib
As per routine clinical practice in the United Kingdom
Repeat Etoricoxib Prescription
One prescription during the Period 1 and, at least, one etoricoxib prescription during Period 2.
Etoricoxib
As per routine clinical practice in the United Kingdom
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etoricoxib
As per routine clinical practice in the United Kingdom
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
collected data deemed to be 'up-to-standard' for research purposes from 1 April 2002 through to 31 December 2015.
* Never registered as a permanent patient of a General Practitioner in the practice
* Registration details were not acceptable (i.e. incomplete data or logically implausible dates)
* Not registered with a General Practitioner for at least 365 days before the date that the patient's first etoricoxib prescription was recorded in the GPRD
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Organon and Co
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Related Links
Access external resources that provide additional context or updates about the study.
EU PAS Register (EUPAS17526)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7013.021
Identifier Type: OTHER
Identifier Source: secondary_id
EMEA/H/A - 31/632
Identifier Type: OTHER
Identifier Source: secondary_id
0663-162
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.